retatrutide nonalcoholic fatty liver disease nash trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic disease: a randomized phase 2a Resmetirom and Thyroid Hormone Receptor‐Targeted

Regulatory and safety landscape Theres a lot of gray market activity

Understanding how to maintain weight loss after tirzepatide is critical for long-term planning

Insulin resistance as a link between amyloid-beta and Tau pathologies in Alzheimers disease

Conclusion: An inflection point in weight management The loss of exclusivity for semaglutide in 2026 marks a strategic turning point in how players operate within the evolving AOM market

In this context, some studies have also been carried out investigating the effect of subcutaneous SMG (compared with placebo) in individuals with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis

The drug keeps you ahead of that signal for a while, but weight loss plateaus within about a year